Skip to main content

tisotumab vedotin

Generic: tisotumab

tisotumab vedotin: 5 clinical trials tracked.

tisotumab vedotin evidence translation

What we can confirm

5 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about tisotumab vedotin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trials (5)

Phase II Study Tisotumab Vedotin in Metastatic or Recurrent Squamous Cell Carcinoma of the Vulva

NCT07672782·Phase 2
Not yet recruiting

Primary endpoint: Overall Response Rate

Interventionalopen28 targetStarted 2026-11Completion 2029-121 site · United StatesGOG Foundation

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

NCT06459180·Phase 3
Active, not recruiting

Primary endpoint: Objective Response Rate (ORR) in Sacituzumab Tirumotecan Run-in

InterventionalRandomizedopen686 targetStarted 2024-07Completion 2028-0650 sites · Argentina, Australia, United StatesMerck Sharp & Dohme LLC

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

NCT04697628·Phase 3·PFE
Completed

Primary endpoint: Overall Survival

InterventionalRandomizedopen502 enrolledStarted 2021-02Completion 2026-0150 sites · United StatesSeagen, a wholly owned subsidiary of Pfizer

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer

NCT03786081·Phase 1/Phase 2·PFE
Terminated

Primary endpoint: Dose escalation: Dose Limiting Toxicities (DLTs)

Interventionalopen214 enrolledStarted 2019-02Completion 2026-0350 sites · Belgium, Czechia, Denmark, Ireland…Seagen, a wholly owned subsidiary of Pfizer

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

NCT03485209·Phase 2·PFE
Active, not recruiting

Primary endpoint: Confirmed Objective Response Rate (ORR) (Parts A, B, C, D, E, F, and G)

Interventionalopen350 enrolledStarted 2018-06Completion 2027-0350 sites · United StatesSeagen, a wholly owned subsidiary of Pfizer